When.com Web Search

  1. Ads

    related to: fda approved gene therapy for sickle cell disease

Search results

  1. Results From The WOW.Com Content Network
  2. FDA approves gene therapy for sickle cell disease: 'One ... - AOL

    www.aol.com/fda-approves-gene-therapy-sickle...

    Sickle cell is the most common disease to receive approval for gene therapy treatment, following decades of development and years of approvals for therapy for people with rarer conditions.

  3. FDA approves cure for sickle cell disease, the first ... - AOL

    www.aol.com/news/fda-approves-cure-sickle-cell...

    The FDA on Friday also approved a second treatment for sickle cell disease, called Lyfgenia, a gene therapy from drugmaker Bluebird Bio. Both treatments work by genetically modifying a patient’s ...

  4. U.S. approves two sickle cell gene therapies, which doctors ...

    www.aol.com/news/u-approves-two-sickle-cell...

    The two gene therapies are the first approved in the U.S. for sickle cell disease. The FDA has previously OK’d 15 gene therapies for other conditions. In the U.S., an estimated 100,000 people ...

  5. US FDA approves two gene therapies for sickle cell disease - AOL

    www.aol.com/news/us-approves-two-gene-therapies...

    By Leroy Leo and Bhanvi Satija (Reuters) -The U.S. Food and Drug Administration (FDA) on Friday approved two gene therapies for sickle cell disease, making one of them the first treatment in the ...

  6. Lovotibeglogene autotemcel - Wikipedia

    en.wikipedia.org/wiki/Lovotibeglogene_autotemcel

    Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease.. The most common side effects include stomatitis (mouth sores of the lips, mouth, and throat), low levels of platelets, white blood cells, and red blood cells, and febrile neutropenia (fever and low white blood cell count), consistent with chemotherapy and ...

  7. Exagamglogene autotemcel - Wikipedia

    en.wikipedia.org/wiki/Exagamglogene_autotemcel

    It was approved in the United States for the treatment of sickle cell disease in December 2023 and for the treatment of transfusion-dependent beta thalassemia in January 2024. [7] [11] [12] Exagamglogene autotemcel is the first cell-based gene therapy treatment utilizing CRISPR/Cas9 gene editing technology to be approved by the US Food and Drug ...

  1. Ad

    related to: fda approved gene therapy for sickle cell disease